Key points from article :
Targeted delivery of functioning TMC1 gene to hair cells in cochlea using engineered virus AAV1.
TMC1 accounts for 4 to 8 percent of genetic deafness. Clinical trials of gene therapy for humans expected within 5 to 10 years.
The study was published in the Science Translational Medicine journal.
